NHRA Logo - Orginal 250.png
Bahrain Oncology Centre Amongst the First in the World to Offer Ground-breaking Sickle Cell and Transfusion Dependent Thalassemia Gene Therapy
May 22, 2024 15:18 ET | National Health Regulatory Authority
MUHARRAQ, Bahrain, May 22, 2024 (GLOBE NEWSWIRE) -- The Bahrain Oncology Centre (BOC) has achieved a significant milestone, becoming amongst the first centres in the World to offer the...
Grand River Hospital
Grand River Hospital adopts Intellijoint HIP to study patient and health system benefits through $1 million provincial investment
April 21, 2022 15:22 ET | Intellijoint Surgical
Kitchener, Ontario, April 21, 2022 (GLOBE NEWSWIRE) -- The adoption of novel medical technologies in Canada, especially those not supported by available funding models, is extremely challenging....
Isracann BioSciences Logo RGB@4x-100 LG.jpg
Isracann Well Positioned for Israel’s Cannabis Sector Growth in 2021
January 19, 2021 09:00 ET | Isracann Biosciences Inc.
VANCOUVER, British Columbia, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc.  (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on...
Axim® Biotechnologies Earns GMP License From Dutch Ministry of Health to Produce Cannabinoid-Based Pharmaceutical Products
October 16, 2018 09:00 ET | AXIM BIOTECHNOLOGIES, INC
New License Allows Leading Cannabinoid Biopharmaceutical Company to Advance Production of Clinical Trial Products NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM®...
Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis
September 23, 2015 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...